Poison pill ruling may weaken French targets

Aventis and Sanofi-Synthelabo are set to merge after a tense three-month standoff. But at what price? Megan Murphy looks at whether a regulatory decision could leave French companies more vulnerable to takeover

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree